SCHEMBL2007252

SCHEMBL2007252

O=C(O)[C@H](CO)N(Cc1ccccc1)C(=O)OCC(Cl)(Cl)Cl

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
POLB P06746 2/20 0.49
LMNA P02545 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
NPC1 O15118 1/20 0.35
GLA P06280 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
PAX8 Q06710 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7363077 0.83 ALDH1A1 (0.54) ALDH1A1POLBLMNAL3MBTL1HSD17B10
SCHEMBL10333560 0.83 ALDH1A1 (0.54) ALDH1A1POLBLMNAL3MBTL1HSD17B10
SCHEMBL3397689 0.78 L3MBTL1 (0.48) ALDH1A1POLBLMNAL3MBTL1HSD17B10
SCHEMBL20576145 0.78 L3MBTL1 (0.48) ALDH1A1POLBLMNAL3MBTL1HSD17B10
SCHEMBL9124694 0.78 L3MBTL1 (0.48) ALDH1A1POLBLMNAL3MBTL1HSD17B10
SCHEMBL3225070 0.78 KMT2A (0.50) ALDH1A1POLBLMNAL3MBTL1HSD17B10
SCHEMBL7753061 0.75 ALDH1A1 (0.45) ALDH1A1POLBLMNAL3MBTL1HSD17B10
SCHEMBL1004997 0.75 ALDH1A1 (0.51) ALDH1A1POLBLMNAL3MBTL1HSD17B10
SCHEMBL1004996 0.75 ALDH1A1 (0.51) ALDH1A1POLBLMNAL3MBTL1HSD17B10
SCHEMBL10420286 0.73 MEN1 (0.43) ALDH1A1POLBLMNAL3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521762-B1 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORP (US) 2014-03-12 EP disclosed
US-7960523-B2 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION (US) 2011-06-14 US disclosed
US-20080033155-A1 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2008-02-07 US disclosed
US-7288640-B2 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION (US) 2007-10-30 US disclosed
US-7232900-B2 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor CORIXA CORPORATION (US) 2007-06-19 US disclosed
WO-2006012425-A2 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2006-02-02 WO disclosed
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) 2005-05-19 US disclosed
EP-1521762-A2 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2005-04-13 EP disclosed
US-20040267007-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor CORIXA CORPORATION 2004-12-30 US disclosed
WO-2004005308-A2 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267007-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor DDOST, STT3A, STT3B ALDH1A1 1755/4885POLB 3690/4885LMNA 4547/4885
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor DDOST, AGL, GALE ALDH1A1 1633/4885POLB 3579/4885LMNA 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.